New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
07:07 EDTMDWDMediWound expands distribution of NexoBrid to South Korea
MediWound announced the signing of an agreement granting BexPharm Korea exclusive rights to market and distribute NexoBrid in South Korea for the treatment of severe burns upon receipt of regulatory approval. An estimated 10,000 patients with severe burns are hospitalized every year in South Korea and primarily are treated at approximately 10 burn centers. In addition to this agreement in South Korea, MediWound has recently executed exclusive distribution agreements for NexoBrid to treat severe burns in Russia with Genfa Medica S.A. and in Argentina with Tuteur S.A.C.I.F.I.A.
News For MDWD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
09:13 EDTMDWDOn The Fly: Pre-market Movers
HIGHER: Mediwound (MDWD), up 25.5% after being awarded a BARDA contract valued up to $112M... Novavax (NVAX), up 8.4% after RSV F vaccine meets safety endpoints in its Phase 1 clinical trial... Western Digital (WDC), up 11.7% after receiving a $3.78B equity investment by Unisplendour Corporation... Esperion Therapeutics (ESPR), up 9.9% after being upgraded to Neutral from Sell at Chardan and after JPMorgan said they still see longer-term upside in the shares... Pericom Semiconductor (PSEM), up 6.5% after Montage Technology proposes to acquire the company for $18.50 per share... Fiat Chrysler (FCAU), up 5.2% after CNBC reported that the company could launch Ferrari's IPO as soon as Friday. NOTABLE: Ralph Lauren (RL), up 6.4% after appointing Gap's (GPS) global president of Old Navy, Stefan Larsson as CEO... Gap is down 7.4%. DOWN AFTER EARNINGS: Barracuda Networks (CUDA), down 28.5%... Costco (COST), down a half a percent.
07:03 EDTMDWDMediWound awarded BARDA contract valued up to $112M
MediWound announces that the U.S. Biomedical Advanced Research and Development Authority, or BARDA, has awarded the Company a contract valued at up to $112M. The contract is for the advancement of the development and manufacturing, as well as the procurement of NexoBrid, the company's proprietary pharmaceutical product for enzymatic removal of eschar in adults with deep-partial and full-thickness thermal burns, as a medical countermeasure as part of BARDA preparedness for mass casualty events. The five-year base contract includes $24M of funding to support development activities to complete the FDA approval process for NexoBrid for use in thermal burn injuries, as well as $16M for procurement of NexoBrid, which is contingent upon FDA Emergency Use Authorization and/or FDA marketing authorization for NexoBrid. In addition, the contract includes options for further funding of up to $22M for expanding NexoBrid's indications and of up to $50M for additional procurement of NexoBrid.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use